net dbt
easd european associ
studi diabet
compani
quicktak beat/rais lower tax
beat/rais lower tax focu us trulic
key takeaway ep y/i our/con
lower cog tax latter reflect net discret tax benefit
resolut incom tax audit time associ impact us tax
reform top-line y/i came our/con
driven diabet portfolio jardianc basaglar key
immunology/oncolog product taltz verzenio trulic global sale in-lin
us trulic came our/con us trulic net sale grew
y/i vs growth higher demand partial off-set lower net price
due higher rebat donut hole impact chang segment mix guidanc
rais ep guid midpoint lower tax partial off-set higher
sg due increas invest support key growth product maintain
neutral base limit catalyst potenti upsid premium multipl
area focu call
call expect investor focu trulic diabet us sale miss
consensu larg due inventori de-stock mix net price focu
call us trulic net price trend back impact increment
donut hole cost inclus rewind data label expect
strength label claim around primari prevent well detail data present
high dose trulic top-lin superior vs current possibl next major
beat consensu howev expect management field question competit
impact felt follow skyrizi launch call remain confid taltz
opportun base uniqu data support fast onset action sustain
efficaci new data gener may establish superior vs competitor tremfya
axspa approv emgal migrain emgal miss consensu
expect updat paid reimburs ratio gross-to-net mix shift specialist
primari care progress secur reimburs ex-u verzenio cancer
anticip impact increment updat includ safeti warn issu
japan today announc overal surviv benefit demonstr
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net interest incom
million
million
compani juli
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani juli
